Fig. 1 · Structure

Documents & Downloads

Ceralasertib (AZD6738)

Cat. No. A15794 CAS 1352226-88-0

ATR inhibitor

AZD6738 is a potent inhibitor of ATR kinase activity with an IC50 of 1 nM against the isolated enzyme and 74 nM against ATR kinase-dependent CHK1 phosphorylation in cells.

In Stock

Publications for Ceralasertib

6 publications citing this product

  1. Joshua J Deppas, .et al. , Toxicol Appl Pharmacol, 2025, Jul:500:117375 PMID: 40339611
  2. Erika Nakatsuka, .et al. , Transl Oncol, 2024, Sep 12:50:102119 PMID: 39270525
  3. Zhiyan Silvia Liu, .et al. , Cancer Res, 2024, Feb 15;84(4):577-597 PMID: 37967363
  4. Yang Lim, .et al. , Science, 2023, Sep 22;381(6664) PMID: 37590370
  5. Brian F Kiesel, .et al. , Cancer Chemother Pharmacol, 2022, Feb;89(2):231-242 PMID: 35066692
  6. Albert Job, .et al. , Sci Rep, 2020, Nov 3;10(1):18924 PMID: 33144657

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AZD6738 (ceralasertib) suppressed break-induced replication in an A549 reporter model. This supports a cellular effect on replication-associated DNA repair; it does not establish a biochemical kinase IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
ATR 1 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 2 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay [PMID: 35191694]
HT-29 GI50 2.6 μM Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay [PMID: 30346772]
LoVo GI50 0.44 μM Cytotoxicity against human LoVo cells after 72 hrs by MTS assay [PMID: 30346772]

Ceralasertib (AZD6738) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Ceralasertib (AZD6738) from 3 published references. In vitro models include A549 cells carrying a break-induced replication (BIR) reporter.

Ceralasertib (AZD6738) In Vitro Studies

In DLD-1 colorectal cancer cells, the POLD1R689W/− clone showed greater sensitivity to AZD6738 than parental and comparison clones after 120 hours. The reported IC50 ratio was 11. The same genotype-dependent response was absent with several common chemotherapies. [2]

Suppression of break-induced replication in an A549 reporter model

Cell-based study · A549 cells carrying a break-induced replication (BIR) reporter [1]

AZD6738 reduced reporter-positive BIR repair relative to DMSO. This cellular repair endpoint is distinct from biochemical ATR potency and from cell viability.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GFP-positive BIR repair populationdirection Reduced at 0.33 and 1.00 μmol/L versus DMSO; no exact percentages inferred from bars.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1, 0.33 and 1.00 μmol/L (Fig. 1F labels)
Exposure duration
72 hours
Method
Single-agent cellular reporter assay
Vehicle
DMSO
Reported limits
Independent replicate count is not explicitly specified in the reviewed Methods/caption; plotted points were not assigned an assumed n.
Methods and source locations

Compound reported in the paper: AZD6738 (ceralasertib); Compound label in the paper: AZD6738

Results apply to the named research material and model; no salt conversion or validation of catalog lot, purity or formulation is implied.

Fig. 1A,F and caption; Results: AZD6738 activates the ATM-dependent signaling pathway and suppresses recombination-mediated DNA repair; Methods: Cell line culture and compounds; Break-induced replication and traffic light reporter assays

GFP-positive BIR repair population: BIR reporter, flow cytometry; reported normalization to combined S–G2 populations of vehicle control. — Fig. 1A,F and caption; Results: AZD6738 activates the ATM-dependent signaling pathway and suppresses recombination-mediated DNA repair; Methods: Cell line culture and compounds; Break-induced replication and traffic light reporter assays

POLD1 genotype modifies the cellular response to AZD6738

Cell-based study · DLD-1 POLD1R689W/− clone compared with parental POLD1+/+, scrambled-guide control and POLD1+/− clone expressing G10V/R506H/S746I [2]

The POLD1R689W/− clone was more sensitive to AZD6738 than the control backgrounds. Common chemotherapies did not show the same genotype-dependent sensitivity, arguing against general drug hypersensitivity in this model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative AZD6738 concentration producing 50% growth inhibitionIC50 ratio 11 (reported control-to-POLD1R689W/− sensitivity ratio); n = 3 independent ATR-inhibitor experiments, triplicate wells per data point; mean ± SEM.[2]
Genotype-dependent inhibition with comparison agentsdirection No POLD1R689W-dependent inhibition with mitomycin C, 5-fluorouracil, carboplatin or oxaliplatin.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Multiple AZD6738 concentrations; Fig. 5A concentration-response curve
Exposure duration
120 hours
Method
Single-agent proliferation assay
Reported limits
Exact tested concentration series and cell-assay solvent are not enumerated in the reviewed Methods; no absolute IC50 estimated from curves.
Methods and source locations

Compound reported in the paper: AZD6738 (ceralasertib); Compound label in the paper: AZD6738

Results apply to the named research material and model; no salt conversion or validation of catalog lot, purity or formulation is implied.

Fig. 5A-C and caption; Results: POLD1R689W-mediated sensitization ... in vitro; Methods: Drugs; Cell proliferation assays; Statistical analysis

Relative AZD6738 concentration producing 50% growth inhibition: 120-hour proliferation assay using SYBRGreen fluorescence; fitted surviving fractions relative to untreated controls. — Fig. 5A-C and caption; Results: POLD1R689W-mediated sensitization ... in vitro; Methods: Drugs; Cell proliferation assays; Statistical analysis

Genotype-dependent inhibition with comparison agents: Parallel proliferation comparisons; n = 3 for mitomycin C/carboplatin and n = 4 for 5-fluorouracil/oxaliplatin; mean ± SEM; two-way ANOVA with Bonferroni post-test. — Fig. 5A-C and caption; Results: POLD1R689W-mediated sensitization ... in vitro; Methods: Drugs; Cell proliferation assays; Statistical analysis

Ceralasertib (AZD6738) In Vivo Studies

In DLD-1 xenografts, oral AZD6738 at 50 mg/kg on a five-days-on/two-days-off schedule for four weeks produced a slower-growth trend in POLD1R689W/− tumors. Group differences were not statistically significant, and parental tumors showed little discernible treatment effect. [2]

A mouse pharmacokinetic study found more-than-dose-proportional systemic exposure across nominal oral doses of 2–75 mg/kg. Measured dosing-solution concentrations differed from nominal doses and were used in the exposure analysis. These are exposure data rather than antitumor efficacy or safety endpoints. [3]

POLD1 xenograft response remained a nonsignificant trend

Animal study · Female NMRI-Foxn1nu/nu nude mice with DLD-1 POLD1+/+ or POLD1R689W/− subcutaneous xenografts [2]

The treated POLD1R689W/− tumors grew more slowly than vehicle-treated mutant tumors, whereas parental tumors showed little discernible treatment effect. Group differences did not reach statistical significance; this experiment supports a trend rather than demonstrated efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative tumor-volume growthdirection No statistically significant tumor-growth difference overall among the four groups; mean ± SEM.[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily, five days on/two days off
Treatment course
Four weeks
Vehicle
10% DMSO, 40% 1,3-propanediol, 50% H2O (as reported)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
POLD1+/+ xenografts
50 mg/kg
Genotype-matched vehicle groupVirtually no discernible growth difference from genotype-matched vehicle controls.[2]
POLD1R689W/− xenografts
50 mg/kg
Genotype-matched vehicle groupSlower growth than genotype-matched vehicle controls, but not statistically significant.[2]
POLD1+/+ xenografts
Model: POLD1+/+ DLD-1 tumors; 9 mice per group
POLD1R689W/− xenografts
Model: POLD1R689W/− DLD-1 tumors; 9 treated mice; 8 vehicle mice
Methods and source locations

Compound reported in the paper: AZD6738 (ceralasertib); Compound label in the paper: AZD6738

Results apply to the named research material and model; no salt conversion or validation of catalog lot, purity or formulation is implied.

Fig. 6A-B and caption; Results: POLD1R689W-mediated sensitization ... in vivo; Discussion paragraph on nonsignificant xenograft results; Methods: Drugs; Xenograft model

Relative tumor-volume growth: Caliper tumor volumes twice weekly, relative to starting treatment volume; no exact curve values extracted. — Fig. 6A-B and caption; Results: POLD1R689W-mediated sensitization ... in vivo; Discussion paragraph on nonsignificant xenograft results; Methods: Drugs; Xenograft model

POLD1+/+ xenografts · Fig. 6A-B and caption; Results: POLD1R689W-mediated sensitization ... in vivo; Discussion paragraph on nonsignificant xenograft results; Methods: Drugs; Xenograft model

POLD1R689W/− xenografts · Fig. 6A-B and caption; Results: POLD1R689W-mediated sensitization ... in vivo; Discussion paragraph on nonsignificant xenograft results; Methods: Drugs; Xenograft model

Nonlinear systemic exposure across oral dose groups

Animal study · Non-tumor-bearing female BALB/c mice; N=3 per time point [3]

Oral exposure rose more than proportionally over the tested dose range. Noncompartmental parameters used measured dosing-solution concentrations; nominal and measured doses differ.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma AZD6738 exposure normalized to actual administered doseAUC0–∞/dose 13.2, 17.0, 24.7 and 27.6 (μg/mL·min)/(mg/kg) for nominal 2.0, 7.5, 20 and 75 mg/kg oral groups, respectively; ANOVA p = 0.0002.[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single administration
Treatment course
Sampling through 1440 min
Vehicle
10% DMSO, 40% propylene glycol, 50% dH2O
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nominal 2.0 mg/kg oral group
2.0 mg/kg nominal; 1.92 mg/kg measured actual dose
Vehicle samples at 5 and 1440 min; comparisons among four oral dose groupsAUC0–∞/actual dose = 13.2 (μg/mL·min)/(mg/kg).[3]
Nominal 7.5 mg/kg oral group
7.5 mg/kg nominal; 8.8 mg/kg measured actual dose
Vehicle samples at 5 and 1440 min; comparisons among four oral dose groupsAUC0–∞/actual dose = 17.0 (μg/mL·min)/(mg/kg).[3]
Nominal 20 mg/kg oral group
20 mg/kg nominal; 23.4 mg/kg measured actual dose
Vehicle samples at 5 and 1440 min; comparisons among four oral dose groupsAUC0–∞/actual dose = 24.7 (μg/mL·min)/(mg/kg).[3]
Nominal 75 mg/kg oral group
75 mg/kg nominal; 90.5 mg/kg measured actual dose
Vehicle samples at 5 and 1440 min; comparisons among four oral dose groupsAUC0–∞/actual dose = 27.6 (μg/mL·min)/(mg/kg).[3]
Nominal 2.0 mg/kg oral group
Model: Female BALB/c mice, 5–7 weeks; N=3 per sampling time
Reported limits: Composite time-point sampling, not longitudinal sampling of each mouse.
Nominal 7.5 mg/kg oral group
Model: Female BALB/c mice, 5–7 weeks; N=3 per sampling time
Reported limits: Composite time-point sampling, not longitudinal sampling of each mouse.
Nominal 20 mg/kg oral group
Model: Female BALB/c mice, 5–7 weeks; N=3 per sampling time
Reported limits: Composite time-point sampling, not longitudinal sampling of each mouse.
Nominal 75 mg/kg oral group
Model: Female BALB/c mice, 5–7 weeks; N=3 per sampling time
Reported limits: Composite time-point sampling, not longitudinal sampling of each mouse.
Methods and source locations

Compound reported in the paper: AZD6738 (ceralasertib); Compound label in the paper: AZD6738

Results apply to the named research material and model; no salt conversion or validation of catalog lot, purity or formulation is implied.

Table 1 (oral groups, exact-dose row, AUC0–∞/dose row and footnotes a,b); Methods: Chemicals and Reagents; Mice; Dose Linearity and Bioavailability; Bioanalysis; Pharmacokinetic Analysis/Noncompartmental Analysis; Results: Dose Linearity and Bioavailability/Noncompartmental Analysis

Plasma AZD6738 exposure normalized to actual administered dose: LC-MS/MS with isotopic internal standard; noncompartmental analysis; normalization used measured actual doses. Table does not give uncertainty for this row. — Table 1 (oral groups, exact-dose row, AUC0–∞/dose row and footnotes a,b); Methods: Chemicals and Reagents; Mice; Dose Linearity and Bioavailability; Bioanalysis; Pharmacokinetic Analysis/Noncompartmental Analysis; Results: Dose Linearity and Bioavailability/Noncompartmental Analysis

Nominal 2.0 mg/kg oral group · Table 1 (oral groups, exact-dose row, AUC0–∞/dose row and footnotes a,b); Methods: Chemicals and Reagents; Mice; Dose Linearity and Bioavailability; Bioanalysis; Pharmacokinetic Analysis/Noncompartmental Analysis; Results: Dose Linearity and Bioavailability/Noncompartmental Analysis

Nominal 7.5 mg/kg oral group · Table 1 (oral groups, exact-dose row, AUC0–∞/dose row and footnotes a,b); Methods: Chemicals and Reagents; Mice; Dose Linearity and Bioavailability; Bioanalysis; Pharmacokinetic Analysis/Noncompartmental Analysis; Results: Dose Linearity and Bioavailability/Noncompartmental Analysis

Nominal 20 mg/kg oral group · Table 1 (oral groups, exact-dose row, AUC0–∞/dose row and footnotes a,b); Methods: Chemicals and Reagents; Mice; Dose Linearity and Bioavailability; Bioanalysis; Pharmacokinetic Analysis/Noncompartmental Analysis; Results: Dose Linearity and Bioavailability/Noncompartmental Analysis

Nominal 75 mg/kg oral group · Table 1 (oral groups, exact-dose row, AUC0–∞/dose row and footnotes a,b); Methods: Chemicals and Reagents; Mice; Dose Linearity and Bioavailability; Bioanalysis; Pharmacokinetic Analysis/Noncompartmental Analysis; Results: Dose Linearity and Bioavailability/Noncompartmental Analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1352226-88-0
Applications ATR inhibitor
Formula C20H24N6O2S
Molecular Weight 412.51
Synonyms AZD-6738
SMILES
C[C@H]1N(C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(C5([S@](=O)(C)=N)CC5)=C2)CCOC1

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 75 mg/mL (181.81 mM)
Water Insoluble
Ethanol Warmed: 38 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+40% propylene glycol+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ceralasertib (AZD6738) Research References

  1. [1] Wilson Z, Odedra R, Wallez Y, et al. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib. Cancer research (2022). PMID: 35078817 DOI: 10.1158/0008-5472.can-21-2997 Source material
  2. [2] Job A, Tatura M, Schäfer C, et al. The POLD1R689W variant increases the sensitivity of colorectal cancer cells to ATR and CHK1 inhibitors. Scientific reports (2020). PMID: 33144657 DOI: 10.1038/s41598-020-76033-1 Source material
  3. [3] Kiesel BF, Guo J, Parise RA, et al. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice. Cancer chemotherapy and pharmacology (2022). PMID: 35066692 DOI: 10.1007/s00280-021-04388-x Source material

Publications

6 publications citing this product

  1. Joshua J Deppas, .et al. , Toxicol Appl Pharmacol, 2025, Jul:500:117375 PMID: 40339611
  2. Erika Nakatsuka, .et al. , Transl Oncol, 2024, Sep 12:50:102119 PMID: 39270525
  3. Zhiyan Silvia Liu, .et al. , Cancer Res, 2024, Feb 15;84(4):577-597 PMID: 37967363
  4. Yang Lim, .et al. , Science, 2023, Sep 22;381(6664) PMID: 37590370
  5. Brian F Kiesel, .et al. , Cancer Chemother Pharmacol, 2022, Feb;89(2):231-242 PMID: 35066692
  6. Albert Job, .et al. , Sci Rep, 2020, Nov 3;10(1):18924 PMID: 33144657

Added to your cart

View Cart Checkout
Loading...